

Whey protein isolate decreases murine stomach weight and intestinal length and alters the expression of Wnt signalling-associated genes

Liam McAllan^{1,2}, John R. Speakman³, John F. Cryan^{4,5} and Kanishka N. Nilaweera^{1*}

¹Teagasc, Moorepark Food Research Centre, Fermoy, County Cork, Republic of Ireland

²Department of Pharmacology and Therapeutics, University College Cork, Cork, Republic of Ireland

³State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, People's Republic of China

⁴Department of Anatomy and Neuroscience, University College Cork, Cork, Republic of Ireland

⁵Alimentary Pharmabiotic Centre, University College Cork, Cork, Republic of Ireland

(Submitted 19 July 2014 – Final revision received 29 October 2014 – Accepted 10 November 2014)

Abstract

The present study examined the underlying mechanisms by which whey protein isolate (WPI) affects energy balance. C57BL/6J mice were fed a diet containing 10% energy from fat, 70% energy from carbohydrate (35% energy from sucrose) and 20% energy from casein or WPI for 15 weeks. Mice fed with WPI had reduced weight gain, cumulative energy intake and dark-phase V_{O_2} compared with casein-fed mice ($P < 0.05$); however, WPI intake had no significant effects on body composition, meal size/number, water intake or RER. Plasma levels of insulin, TAG, leptin, glucose and glucagon-like peptide 1 remained unchanged. Notably, the intake of WPI reduced stomach weight and both length and weight of the small intestine ($P < 0.05$). WPI intake reduced the gastric expression of *Wnt5a* ($P < 0.01$) and *Fzd4* ($P < 0.01$), with no change in the expression of receptor tyrosine kinase-like orphan receptor 2 (*Ror2*) and LDL receptor-related protein 5 (*Lrp5*). In the ileum, WPI increased the mRNA expression of *Wnt5a* ($P < 0.01$) and caused a trend towards an increase in the expression of *Fzd4* ($P = 0.094$), with no change in the expression of *Ror2* and *Lrp5*. These genes were unresponsive in the duodenum. Among the nutrient-responsive genes, WPI specifically reduced ileal mRNA expression of peptide YY ($P < 0.01$) and fatty acid transporter protein 4 ($P < 0.05$), and decreased duodenal mRNA expression of the insulin receptor ($P = 0.05$), with a trend towards a decreased expression of Na–glucose co-transporter 1 ($P = 0.07$). The effects of WPI on gastrointestinal Wnt signalling may explain how this protein affects gastrointestinal structure and function and, in turn, energy intake and balance.

Key words: Whey proteins: Stomach: Intestine: Energy intake

Whey proteins are a by-product of cheese manufacturing. In recent years, these dietary proteins have gained considerable interest in relation to their health benefits, including reduction in energy intake and body weight, and improvement in insulin sensitivity^(1,2). However, more research is required to assess whether the effects of whey protein are dependent on macronutrient composition in the diet, as demonstrated previously for diets enriched with whey protein⁽³⁾, as this will allow the formulation of diets with the optimum macronutrient combination that confers specific beneficial effects on human health. Furthermore, such analysis may also reveal the mechanisms underpinning the effects of these proteins.

We have previously shown that intake of 20% energy from whey protein isolate (WPI) reduces weight gain and fat mass,

and increases lean mass in mice fed a high-fat (45% energy) diet^(4,5). In contrast, intake of a high whey protein content (above the 14–25% adequate energy range) has been shown to influence energy balance in mice fed a low-fat diet (10% energy from fat). Moreover, where an effect is found, the underlying mechanisms have not been elucidated. For instance, mice fed a diet containing 30% energy from whey protein and 10% energy from fat exhibited reduced energy intake and weight gain by 1 week compared with mice fed a similar diet but with either soya or gluten as the protein source⁽⁶⁾. A reduction in cumulative energy intake was observed in rats fed a diet containing 42% energy from protein (26% whey and 16% albumin) between 5 and 10 weeks compared with those fed a similar diet but whey

Abbreviations: *Fzd4*, frizzled 4; GLP-1, glucagon-like peptide 1; *IR*, insulin receptor; LF-CAS, 10% energy from fat and 35% energy from sucrose with 20% energy from casein; LF-WPI, 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate; *Wnt5a*, *Wnt5a*; WPI, whey protein isolate.

* **Corresponding author:** Dr K. N. Nilaweera, fax +353 25 42 340, email kanishka.nilaweera@teagasc.ie

replaced by either albumin or soya protein⁽⁷⁾. In contrast, when energy from dietary protein was reduced to 15 or 25%, with energy from fat being maintained at about 9 and 15%, respectively, whey protein did not affect energy intake and body-weight gain^(8,9). Interestingly, the latter studies assessed food intake only for a period of 2 or 7 weeks, in comparison to the study on high whey protein, in which the reduction in energy intake occurred by week 5 and continued up to 10 weeks⁽⁷⁾. Thus, this discrepancy in the data could be attributed to the test duration, where a longer duration is required when an adequate proportion of energy derived from protein is used in test diets. Thus, the purpose of the present study was to assess whether WPI at 20% energy in a diet containing 10% energy from fat alters energy balance and, where there is an effect, to explore the underlying mechanisms. The study lasted for 15 weeks in consideration of the previous published data showing that whey protein (at an adequate range) did not affect energy balance up to 7 weeks^(8,9).

Materials and methods

Animals and diets

All procedures involving animals were approved by the University College Cork Animal Experimentation Ethics Committee (2011/005) and were licensed under the Cruelty to Animals Act 1876. Male C57BL/6J mice (Harlan), aged 3 weeks old, were singly housed and had *ad libitum* access to food and water throughout the trial. Mice were initially fed a diet containing 10% energy from fat and 35% energy from sucrose with 20% energy from casein (LF-CAS, #D12450; Research Diets) during the acclimatisation period lasting for 3 weeks.

Experimental protocol

Following acclimatisation, singly housed mice were separated into two weight-matched dietary groups (*n* 8 animals per group) and provided with either the LF-CAS diet or a similar diet containing 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate (LF-WPI, AlacenTM 895; NZMP) for a total of 15 weeks. Further details of the diet composition can be found in online Supplementary Table S1. Body weight and energy intake were measured weekly. In addition, at week 14, feeding behaviour and metabolic activity were measured using the TSE PhenoMaster System (TSE Systems GmbH) comprising eight test cages and one reference cage. Mice were housed individually in the test cages. After a 2 d acclimatisation period, metabolic parameters were measured on the 3rd day. Sensors recorded metabolic parameters in the cages sequentially, with each cage being analysed for 1 min, such that data collected over a 24 h period corresponded to intervals of 9 min for the eight test cages and one reference cage. Body composition was determined by NMR using a Bruker Minispec LF50H (Bruker Optics) at the end of the study, following a 6–8 h fast. Subsequently, mice were anaesthetised and blood was collected. Mice were then killed by cervical dislocation.

Tissues of interest were excised and weighed. Small-intestinal luminal contents were removed by mechanical expulsion and tissue length was determined. Tissue was weighed, and 2 cm sections from the proximal and distal parts of the intestine that were 2 cm away from the start and end of the intestine, respectively, were excised for the analysis of gene expression in the duodenum and ileum. All tissues were immediately snap-frozen in liquid N₂. Plasma and tissue samples were stored at –80°C until analysis.

Biochemical analysis

Blood collected into EDTA-containing vacutainer tubes (BD) from anaesthetised mice (ketamine, 65 mg/kg and xylazine, 13 mg/kg) was treated with diprotin A and aprotinin, as described previously⁽⁴⁾, to protect plasma peptides against proteolytic degradation. Plasma was isolated by centrifugation at 2000 rpm for 15 min at 4°C, and plasma concentrations of glucose (Calbiochem) and TAG (LabAssay TAG; Wako Chemicals) were analysed using colorimetric assay kits. ELISA kits were used to determine plasma concentrations of glucagon-like peptide 1 (GLP-1; Millipore), leptin and insulin (Crystal Chem). Homeostasis model assessment of insulin resistance was calculated as described previously⁽⁴⁾.

Tissue gene expression

Total RNA was isolated from tissues of interest (epididymal adipose tissue, liver, skeletal muscle, duodenum and ileum) using RNeasy mini kits (Qiagen) with subsequent DNase treatment to prevent genomic DNA contamination. Duodenal and ileal total RNA was isolated from representative intact tissue segments. Complementary DNA was synthesised from 1 µg of isolated total RNA and subjected to real-time quantitative PCR analysis, as described previously⁽⁴⁾. Primer sequences of target and reference genes are listed in online Supplementary Table S2. The mRNA expression of target genes was calculated by the 2^{–ΔΔCp} (crossing point) method, after normalising against the expression of the reference gene according to the following formula:

$$\Delta\Delta C_p = \Delta C_p(\text{target gene}) - \Delta C_p(\text{reference gene}).$$

β-Actin (adipose, liver, muscle, duodenum and ileum), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (*YWHAZ*) (liver, duodenum and ileum) and *18S* (adipose) were used as the reference genes. In instances where two housekeeping genes were used, a geometric mean was determined for normalisation. Gene expression is shown relative to the LF-CAS group.

Statistical analysis

Data are presented as means with their standard errors. The effects of dietary treatments were analysed by unpaired *t* tests. A two-way repeated-measures ANOVA with Bonferroni's multiple comparisons was used to analyse body-weight trajectories over the treatment periods. Mann–Whitney *U* tests

were used to analyse non-parametric data. V_{O_2} data were analysed by ANCOVA (SAS software version 9.3), with total body weight being used as the covariant, as described previously⁽¹⁰⁾. Significance was set at $P \leq 0.05$, using GraphPad Prism (version 6; GraphPad Software Inc.), SAS software (version 9.3; SAS Institute Inc.) and Minitab (version 15; Minitab Ltd).

Results

Effect whey protein isolate on weight gain and body composition

Cumulative energy intake was significantly reduced in the LF-WPI group over the first 13 weeks, and this significance was observed from week 11 onwards ($P < 0.05$; Fig. 1(d)). In contrast, body-weight gain was not significantly different at week 11 (6.17 (SE 0.28) g for the LF-WPI group *v.* 7.05 (SE 0.54) g for the LF-CAS group; $P = 0.17$), but reached significance by week 12 (5.89 (SE 0.24) g for the LF-WPI group *v.* 7.5 (SE 0.61) g for the LF-CAS group; $P < 0.05$). Although after 15 weeks of dietary treatments, total body-weight gain was significantly reduced in the LF-WPI group compared with the LF-CAS group ($P < 0.05$; Fig. 1(b)), there was no significant difference observed in either body weight or body composition (percentage of fat or lean mass) between the two groups (Fig. 1(a) and (c), respectively). Consistent with the overall percentage of body fat mass, the mass of both subcutaneous and epididymal adipose tissue depots was not significantly different between the LF-CAS and LF-WPI groups (Fig. 2(a)).




Fig. 1. Effect of whey protein isolate on energy balance-related parameters. Mice were fed a diet containing either 10% energy from fat and 35% energy from sucrose with 20% energy from casein (LF-CAS) or 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate (LF-WPI) for 15 weeks. (a) Body-weight trajectories over the period of 15 weeks are shown (○, LF-CAS; ●, LF-WPI), together with (b) weight gain, (c) body composition and (d) cumulative energy intake over the first 13 weeks. □, LF-CAS; ■, LF-WPI. Values are means ($n = 8$), with their standard errors represented by vertical bars. Mean value was significantly different from that of the LF-CAS group: * $P < 0.05$, ** $P < 0.01$.




Fig. 2. Effect of whey protein isolate on (a) tissue weight and (b) small-intestinal length. Mice fed a diet containing either 10% energy from fat and 35% energy from sucrose with 20% energy from casein (□, LF-CAS) or 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate (■, LF-WPI) for 15 weeks. Tissue weight is shown relative to casein. Values are means ($n = 8$), with their standard errors represented by vertical bars. Mean value was significantly different from that of the LF-CAS group: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. SAT, subcutaneous white adipose tissue; EAT, epididymal white adipose tissue.

Effect of whey protein isolate on energy intake and metabolic parameters

A further analysis of energy intake using the TSE PhenoMaster cages in week 14 (Table 1) showed a reduction of energy intake during the dark phase in the LF-WPI group, although this was not significant. Also, no significant effects were observed for the 24 h meal pattern, represented by meal number and size, RER, and water intake; however, there was a reduction in V_{O_2} during the dark phase in the LF-WPI group and also a trend towards a decrease in V_{O_2} during the light phase (Table 1), as revealed by the analysis of metabolic data independent of the body weights of mice.

Effect of whey protein isolate on the gastrointestinal tract

The LF-WPI group had reduced stomach and small-intestinal weights relative to the LF-CAS group after 15 weeks of dietary treatments, which also corresponded with a concomitant reduction in small-intestinal length (Fig. 2).

At the cellular level, WPI intake reduced the gene expression of Wingless/int-1 5a (*Wnt5a*) and frizzled 4 (*Fzd4*) in the stomach, but not the expression of receptor tyrosine kinase-like orphan receptor 2 (*Ror2*) and LDL receptor-related protein 5 (*Lrp5*) (Fig. 3(a)). In the ileum, WPI increased the mRNA expression of *Wnt5a* and caused a trend towards an increase in the gene expression of *Fzd4* ($P = 0.094$; Fig. 3(c)). In the duodenum, the Wnt signalling-associated genes did not respond to the WPI treatment (Fig. 3(b)). However, in the same region, WPI intake caused a trend towards a decrease in the gene expression of insulin receptor (*IR*) and Na-glucose co-transporter 1 (*SGLT-1*), with no change in the expression of insulin receptor substrate 1 (*IRS-1*), *GLUT2* or glucose-dependent insulinotropic peptide (*GIP*) (Table 2). WPI intake decreased the gene expression of cholecystokinin (*CCK*), but not significantly (Table 2). In the ileum, WPI intake increased the gene expression of *GLUT2*, but decreased the expression of fatty acid transporter protein 4 (*FAITP4*) (Table 2). The expression of proglucagon in the ileum was unaffected by WPI intake (Table 2), which correlated with plasma GLP-1 levels (Table 3); however, WPI reduced the gene expression of peptide YY (*PYY*) (Table 2).

Table 1. Metabolic parameters in mice fed a diet containing either 10% energy from fat and 35% energy from sucrose with 20% energy from casein (LF-CAS) or 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate (LF-WPI) at week 14

(Mean values with their standard errors)

	Phase	LF-CAS (n 8)		LF-WPI (n 8)		P
		Mean	SE	Mean	SE	
Energy intake (kJ/mouse)	Light	12.17	1.46	10.40	2.42	NS
	Dark	43.06	2.10	32.86	3.91	NS
Meal number	Light	13.0	1.1	20.3	5.0	NS
	Dark	31.9	2.9	25.4	3.0	NS
Meal size (kJ)	Light	0.99	0.16	0.80	0.12	NS
	Dark	1.46	0.20	1.15	0.19	NS
Water intake (ml/mouse)	Light	0.61	0.10	0.82	0.22	NS
	Dark	2.83	0.32	3.65	0.69	NS
V _{O2} (ml/h)	Light	91.8	2.58	84.94	2.58	0.097
	Dark	104.83	1.54	98.74	1.54	<0.05
RER (V _{CO2} /V _{O2})	Light	0.83	0.01	0.82	0.03	NS
	Dark	0.98	0.01	0.92	0.02	NS

V_{CO2}, CO₂ production.

Investigation of the same tissues in a previous published study conducted in mice fed a similar LF-CAS and LF-WPI diet for 7 weeks⁽⁵⁾ revealed that while the stomach weight was not different between the two groups (1.06 (SE 0.10) for the LF-WPI group *v.* 1.00 (SE 0.048) for the LF-CAS group; data are shown relative to the LF-CAS group, which is set at 1.00), the intestinal weight was reduced in the LF-WPI group relative to the LF-CAS group (0.73 (SE 0.026) for the LF-WPI group *v.* 1.00 (SE 0.035) for the LF-CAS group; $P < 0.001$; data are shown relative to the LF-CAS group, which is set at 1.00), as was the intestinal length (33.65 (SE 0.38) cm for the LF-WPI group *v.* 35.64 (SE 0.70) cm for the LF-CAS group; $P < 0.05$).

Effect of whey protein isolate on plasma hormones and metabolites and lipid metabolic-related gene expression

Although WPI intake did not affect plasma leptin (Table 3) and related epididymal gene expression levels (Fig. 4), or plasma levels of TAG, insulin and glucose (Table 3), epididymal expression levels of fatty acid synthase (*FASN*), acetyl-CoA carboxylase (*ACC*) and cluster of differentiation 36 (*CD36*) were significantly up-regulated in the LF-WPI group compared with the LF-CAS group at week 15 (Fig. 4). Additionally, there was a trend towards an increase in the gene expression of lipoprotein lipase ($P = 0.08$; Fig. 4). The genes involved in insulin signalling (*IR*, *GLUT4* and *IRS-1*), fatty acid catabolism (β 3-adrenergic receptor (*β 3-AR*), hormone-sensitive lipase (*HSL*), carnitine palmitoyltransferase 1b (*CPT1b*) and uncoupling protein 2 (*UCP-2*)) and adipogenesis (*PPAR γ*) were unaltered by WPI intake (Fig. 4). None of the insulin signalling or lipid metabolism-related genes was altered by WPI intake in the muscle or liver (see online Supplementary Tables S3 and S4), with the exception of *IRS-1*, which showed a trend towards a decrease in expression in the muscle of the LF-WPI group compared with the LF-CAS group (see online Supplementary Table S3).

Discussion

The results from the present study showed that intake of WPI for 15 weeks decreased weight gain, cumulative energy intake and dark-phase metabolic activity (V_{O2}), which was accompanied by a reduction in stomach weight and intestinal length and weight in mice fed a low-fat diet. WPI-fed mice exhibited reduced cumulative energy intake by week 11. Dark-phase metabolic activity, measured at week 14, also decreased in the LF-WPI group compared with the LF-CAS group. The reduced body-weight gain with WPI intake could thus be a consequence of the gradual decrease in cumulative energy intake occurring before the change in the metabolic rate. Intestinal satiation/satiety-related *CCK* and proglucagon genes were unresponsive to the intake of WPI, as was plasma GLP-1 levels. Moreover, ileal expression of *PYY*, which reduces energy intake⁽¹¹⁾, was significantly decreased in the LF-WPI group compared with the LF-CAS group. These data suggest that modulation of the production of these satiety and satiation hormones was not the mechanism by which WPI reduces cumulative energy intake.

The present data show that WPI intake reduces intestinal length. Given the association between the reduction in intestinal length and weight loss⁽¹²⁾, herein, we sought to obtain further evidence supporting a link between WPI-induced changes in intestinal cellular activity and energy balance in mice by investigating nutrient-responsive genes in the duodenum and ileum. Consistent with a reduced nutrient contact with or passage through the intestinal cells, duodenal gene expression of *IR* and *SGLT-1*, which is responsive to glucose⁽¹³⁾, showed a decreased trend in the LF-WPI group compared with the LF-CAS group. In the ileum, the cellular lipid transport protein *FATP4*⁽¹⁴⁾ and *PYY*, which are mainly responsive to the availability of fat⁽¹⁵⁾, were both significantly decreased by WPI intake. Although duodenal mRNA expression of *GLUT2*, the protein product of which is predominantly found at the basolateral membrane of enterocytes⁽¹⁶⁾, was




Fig. 3. Effect of whey protein isolate on the gene expression of gastrointestinal Wnt signalling. Mice were fed a diet containing either 10% energy from fat and 35% energy from sucrose with 20% energy from casein (□, LF-CAS) or 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate (■, LF-WPI) for 15 weeks. mRNA expression levels were measured in the (a) stomach, (b) duodenum and (c) ileum. Gene expression is shown relative to the LF-CAS group, which was set at 1.00. Values are means (*n* 6–8), with their standard errors represented by vertical bars. Mean value was significantly different from that of the LF-CAS group: ***P* < 0.01. *Wnt5a*, Wingless/int-1 5a; *Ror2*, receptor tyrosine kinase-like orphan receptor 2; *Fzd4*, frizzled 4; *Lrp5*, LDL receptor-related protein 5.

increased by WPI intake, one could argue based on other nutrient-responsive genes that this change may represent a feedback mechanism to the lower availability of nutrients in the luminal side of the intestine. The intestinal gene expression data are consistent with the changes in cumulative energy intake in mice.

To ascertain the time frame of the changes in intestinal length and weight relative to energy intake, we investigated

the same tissues in an earlier published study conducted in mice fed the same LF-CAS and LF-WPI diets, but the study was terminated at week 7⁽⁵⁾. In that study, by week 7, mice fed with WPI consumed a similar energy content to their casein-fed counterparts, and had reduced intestinal weights and lengths similar to those observed in the present study. Therefore, this suggests that the reduction in cumulative energy intake, which reached significance compared with casein-fed mice by week 11, occurred after the morphological change in the intestine. It is noteworthy that obese (*ob/ob*) mice have longer intestines⁽¹⁷⁾ and that the development of high-fat diet-induced obesity in mice also increases villus length and cells per villus⁽¹⁸⁾. Moreover, a recent study has shown that WPI intake reduced growth-related parameters within the first week of dietary intake⁽¹⁹⁾. The data from the present study also show that WPI intake reduced stomach weight in mice. In contrast, in our previous published study conducted for 7 weeks, mice fed with WPI had an unaltered stomach weight, suggesting that the reduction in stomach weight occurred between 7 and 15 weeks of WPI intake, after the reduction in intestinal length. Together, these data suggest a potential functional relationship between WPI-induced changes in the gastrointestinal tract and energy intake.

Organ development is in part regulated by the Wnt/ β -catenin pathway involving Wnt proteins, Fzd and Lrp-5/6 receptor complexes, which interact and mediate the effects through β -catenin proteins⁽²⁰⁾. Notably, *Wnt5a* has been shown to act independently of the β -catenin pathway (non-canonical signalling); however, recent data suggest that it can also inhibit and stimulate the canonical Wnt/ β -catenin pathway by acting through the *Ror2* receptor, which has been revealed by the

Table 2. Intestinal gene expression in mice fed a diet containing either 10% energy from fat and 35% energy from sucrose with 20% energy from casein (LF-CAS) or 10% energy from fat and 35% energy from sucrose with 20% energy from whey protein isolate (LF-WPI) for 15 weeks*

(Mean values with their standard errors)

	LF-CAS (<i>n</i> 6–8)		LF-WPI (<i>n</i> 6–8)		<i>P</i> †
	Mean	SE	Mean	SE	
Duodenum					
<i>IR</i>	1.00	0.12	0.68	0.09	0.05
<i>GLUT2</i>	1.00	0.09	0.94	0.06	NS
<i>IRS-1</i>	1.00	0.09	0.84	0.07	NS
<i>SGLT-1</i>	1.00	0.07	0.83	0.05	0.07
<i>CCK</i>	1.00	0.05	0.76	0.15	NS
<i>GIP</i>	1.00	0.10	0.65	0.15	NS
<i>FATP4</i>	1.00	0.06	1.13	0.13	NS
Ileum					
<i>IR</i>	1.00	0.04	1.00	0.07	NS
<i>GLUT2</i>	1.00	0.21	1.89	0.31	<0.05
<i>IRS-1</i>	1.00	0.06	1.13	0.17	NS
<i>SGLT-1</i>	1.00	0.09	0.99	0.10	NS
Proglucagon	1.00	0.07	1.13	0.17	NS
<i>PYY</i>	1.00	0.11	0.60	0.06	<0.01
<i>FATP4</i>	1.00	0.08	0.77	0.04	<0.05

IR, insulin receptor; *IRS-1*, insulin receptor substrate 1; *SGLT-1*, Na–glucose co-transporter 1; *CCK*, cholecystokinin; *GIP*, glucose-dependent insulinotropic peptide; *FATP4*, fatty acid transporter protein 4; *PYY*, peptide YY.

* Gene expression is shown relative to the LF-CAS group, which was set at 1.00. † Values differed significantly at *P* < 0.05.

Table 3. Plasma parameters in mice fed a diet containing either 10 % energy from fat and 35 % energy from sucrose with 20 % energy from casein (LF-CAS) or 10 % energy from fat and 35 % energy from sucrose with 20 % energy from whey protein isolate (LF-WPI) for 15 weeks (Mean values with their standard errors)

	LF-CAS (n 8)		LF-WPI (n 8)		P
	Mean	SE	Mean	SE	
Plasma TAG (mmol/l)	0.41	0.02	0.38	0.03	NS
Plasma leptin (ng/ml)	6.65	1.53	5.80	1.38	NS
Plasma GLP-1 (pM)	24.70	3.50	23.59	1.50	NS
Plasma glucose (mmol/l)	12.18	1.57	13.11	0.84	NS
Plasma insulin (ng/ml)	0.21	0.01	0.22	0.01	NS
HOMA-IR	3.07	0.39	3.12	0.16	NS

GLP-1, glucagon-like peptide 1; HOMA-IR, homeostasis model assessment of insulin resistance.

generation of transgenic mice overexpressing *Wnt5a*⁽²¹⁾ and by the overexpression of *Fzd4* and *Lip5* in 293 cells, where experimental manipulation allowed *Wnt5a* to stimulate Wnt/ β -catenin signalling pathway⁽²²⁾. Notably, mice ectopically expressing *Wnt5a* were stillborn and had reduced stomach and intestinal tracts⁽²¹⁾. Interestingly, targeted deletion of the *Wnt5a* gene in mice also caused changes in the gastrointestinal tract⁽²³⁾ similar to mice overexpressing the same gene⁽²¹⁾. Contrasting genetic manipulations of *Wnt5a* resulting in similar gastrointestinal features in mice suggest a complex interplay between the non-canonical Wnt5a signalling pathway and the Wnt/ β -catenin pathway. This complexity is further highlighted in the present study, as the gene expression of *Wnt5a* and *Fzd4* decreased in the stomach of the LF-WPI group compared with the LF-CAS group, while the same genes in the ileum responded to the protein intake by increasing their expression, yet the two tissues reduced in weight. In contrast, neither gene was affected by WPI in the duodenum, with *Ror2* and *Lip5* remaining unchanged throughout the gastrointestinal tract where their gene expression was investigated. Importantly, the present study demonstrates that Wnt signalling-associated genes in the gastrointestinal tract are responsive to WPI. We speculate that the regional-specific expression and actions of

Wnt5a and *Fzd4* and associated inhibitory or stimulatory effects on the Wnt/ β -catenin signalling pathway underlie the observed changes in the gastrointestinal tract of WPI-fed mice, which, in turn, modulate energy intake and body-weight gain.

Although whey protein intake has been shown to cause an insulinotropic effect^(24,25), in the present study, WPI did not alter plasma levels of insulin, glucose or GLP-1, intestinal expression of *GIP*, or insulin signalling-associated genes in the liver, muscle or epididymal tissues. The lack of an insulinotropic effect could be due to the reduction in cumulative energy intake and associated reduced nutrient availability and/or due to the high sucrose content in the diet, which has previously been shown to cause glucose intolerance and impair GLP-1 secretion in mice⁽²⁶⁾. Notably, there was a trend towards a decrease in the expression of *IR* in the duodenum in response to WPI intake. It remains to be determined whether this was related to the altered intestinal morphology because insulin action in the intestine has been shown to promote greater enterocyte turnover, which correlates with the expression of *IR* in the villus-crypt axis⁽²⁷⁾.

In the present study, there was a mismatch in the time frame of decreased cumulative energy intake and body-weight gain as the former decreased by week 11, while body-weight gain was significantly different by week 12. Even at the end of the study, the plasma TAG level was not different between the two groups of mice, nor was the percentage of fat content in the body or specifically in the epididymal and subcutaneous fat pads. In this respect, it is noteworthy that the epididymal expression of lipogenic ACC and FASN increased in association with a concurrent increased expression of the fatty acid transporter CD36⁽²⁸⁾. These data suggest increased lipogenesis in the epididymal adipose tissue, which may play a role in maintaining energy homeostasis causing a mismatch in the time frame between decreased cumulative energy intake and body weight. In line with this suggestion, metabolic activity, measured at week 14, also decreased by WPI intake, presumably because of decreasing cumulative energy in mice with an altered gastrointestinal tract. In




Fig. 4. Effect of whey protein isolate on the expression of epididymal adipose tissue genes. Mice were fed a diet containing either 10 % energy from fat and 35 % energy from sucrose with 20 % energy from casein (□, LF-CAS) or 10 % energy from fat and 35 % energy from sucrose with 20 % energy from whey protein isolate (■, LF-WPI) for 15 weeks. The expression levels of epididymal adipose tissue genes were measured. Gene expression is shown relative to the LF-CAS group, which was set at 1.00. The genes investigated were insulin receptor (*IR*), *GLUT4*, insulin receptor substrate 1 (*IRS-1*), β 3-adrenergic receptor (*β 3-AR*), hormone-sensitive lipase (*HSL*), carnitine palmitoyltransferase 1b, (*CPT1b*), uncoupling protein 2 (*UCP-2*), *PPAR γ* , lipoprotein lipase (*LPL*), fatty acid transporter protein 1 (*FATP1*), cluster of differentiation 36 (*CD36*), fatty acid synthase (*FASN*), acetyl-CoA carboxylase (*ACC*) and leptin. Values are means (n 8), with their standard errors represented by vertical bars. Mean value was significantly different from that of the LF-CAS group: * $P < 0.05$, ** $P < 0.01$.

contrast, in our previous published studies, WPI at 20% energy content in a diet with 45% energy from fat reduced fat mass and normalised energy intake without affecting metabolic activity in mice at 8 and 21 weeks compared with the casein-fed control^(4,5). In the latter studies, data for metabolic activity were shown relative to body weight (ml/h per kg). In light of the suggestion that ANCOVA is a more suitable statistical method to identify the effects of the diet on metabolic activity independent of body-weight changes, we reanalysed these previously published data using ANCOVA⁽¹⁰⁾. Again, as with our previously published V_{O2} data (in ml/h per kg)⁽⁴⁾, there was no significant effect of WPI on V_{O2} (ml/h) independent of the body weight in mice fed a high-fat diet with WPI (data not shown). Thus, the contrasting effects of WPI on energy intake, fat mass and metabolic activity in the previously published studies^(4,5) compared with the present study could be related to how whey proteins affect energy balance in a background of altered fat to carbohydrate content in the diet.

In conclusion, the results herein show that 20% energy from WPI in a diet containing 10% energy from fat and 35% energy from sucrose reduced cumulative energy intake, dark-phase metabolic activity and body-weight gain. This is accompanied by a decreased intestinal length and weight, as well as stomach weight, which was correlated with an altered expression of Wnt signalling-associated genes. Further investigations are required to determine the significance of the alteration to the intestinal environment uncovered herein for the regulation of energy balance.

Supplementary material

To view supplementary material for this article, please visit <http://dx.doi.org/10.1017/S0007114514004024>

Acknowledgements

K. N. N. was supported by the Teagasc Vision Programme on Obesity (RMIS5974). L. M. was supported by the Teagasc Walsh Fellowship. J. R. S. was supported by a 1000-talents professorship from the Chinese government. The funding bodies had no input on the design of the study or in the interpretation of the data.

The authors' contributions are as follows: L. M., J. R. S., J. F. C. and K. N. N. designed the study; K. N. N. and J. F. C. obtained ethical approval for the study; L. M. performed the experiments; L. M. and J. R. S. analysed the data; L. M. generated the figures. All authors contributed to the drafting of the manuscript. All authors approved the final version for submission.

The authors declare that there is no competing interest.

References

1. Krissansen GW (2007) Emerging health properties of whey proteins and their clinical implications. *J Am Coll Nutr* **26**, 713S–723S.
2. Luhovyy BL, Akhavan T & Anderson GH (2007) Whey proteins in the regulation of food intake and satiety. *J Am Coll Nutr* **26**, 704S–712S.
3. Pichon L, Potier M, Tome D, *et al.* (2008) High-protein diets containing different milk protein fractions differently influence energy intake and adiposity in the rat. *Br J Nutr* **99**, 739–748.
4. McAllan L, Keane D, Schellekens H, *et al.* (2013) Whey protein isolate counteracts the effects of a high-fat diet on energy intake and hypothalamic and adipose tissue expression of energy balance-related genes. *Br J Nutr* **110**, 2114–2126.
5. McAllan L, Skuse P, Cotter PD, *et al.* (2014) Protein quality and the protein to carbohydrate ratio within a high fat diet influences energy balance and the gut microbiota in C57BL/6J mice. *PLOS ONE* **9**, e88904.
6. Yu Y, South T & Huang XF (2009) Inter-meal interval is increased in mice fed a high whey, as opposed to soy and gluten, protein diets. *Appetite* **52**, 372–379.
7. Zhou J, Keenan MJ, Lusso JN, *et al.* (2011) Dietary whey protein decreases food intake and body fat in rats. *Obesity* **19**, 1568–1573.
8. Morifuji M, Sakai K, Sanbongi C, *et al.* (2005) Dietary whey protein increases liver and skeletal muscle glycogen levels in exercise-trained rats. *Br J Nutr* **93**, 439–445.
9. Teixeira KR, Silva ME, Neves LX, *et al.* (2012) Whey protein improves HDL/non-HDL ratio and body weight gain in rats subjected to the resistance exercise. *Braz Arch Biol Technol* **55**, 943–950.
10. Tschop MH, Speakman JR, Arch JR, *et al.* (2012) A guide to analysis of mouse energy metabolism. *Nat Methods* **9**, 57–63.
11. Cummings DE & Overduin J (2007) Gastrointestinal regulation of food intake. *J Clin Invest* **117**, 13–23.
12. Brodin RE, LaMarca LB, Kenler HA, *et al.* (2002) Malabsorptive gastric bypass in patients with superobesity. *J Gastrointest Surg* **6**, 195–203; discussion 204–205.
13. Gorboulev V, Schurmann A, Vallon V, *et al.* (2012) Na⁺-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. *Diabetes* **61**, 187–196.
14. Stahl A, Hirsch DJ, Gimeno RE, *et al.* (1999) Identification of the major intestinal fatty acid transport protein. *Mol Cell* **4**, 299–308.
15. Maljaars J, Peters HP & Masclee AM (2007) Review Article: the gastrointestinal tract: neuroendocrine regulation of satiety and food intake. *Aliment Pharmacol Ther* **26**, Suppl. 2, 241–250.
16. Roder PV, Geillinger KE, Zietek TS, *et al.* (2014) The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. *PLOS ONE* **9**, e89977.
17. Morton AP & Hanson PJ (1984) Monosaccharide transport by the small intestine of lean and genetically obese (ob/ob) mice. *Q J Exp Physiol* **69**, 117–126.
18. de Wit NJ, Bosch-Vermeulen H, de Groot PJ, *et al.* (2008) The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. *BMC Med Genomics* **1**, 14.
19. Tranberg B, Madsen AN, Hansen AK, *et al.* (2015) Whey-reduced weight gain is associated with a temporary growth reduction in young mice fed a high-fat diet. *J Nutr Biochem* **26**, 9–15.
20. MacDonald BT, Tamai K & He X (2009) Wnt/ β -catenin signaling: components, mechanisms, and diseases. *Dev Cell* **17**, 9–26.



21. van Amerongen R, Fuerer C, Mizutani M, *et al.* (2012) Wnt5a can both activate and repress Wnt/ β -catenin signaling during mouse embryonic development. *Dev Biol* **369**, 101–114.
22. Mikels AJ & Nusse R (2006) Purified Wnt5a protein activates or inhibits β -catenin-TCF signaling depending on receptor context. *PLoS Biol* **4**, e115.
23. Cervantes S, Yamaguchi TP & Hebrok M (2009) Wnt5a is essential for intestinal elongation in mice. *Dev Biol* **326**, 285–294.
24. Drucker DJ (2006) Enhancing the action of incretin hormones: a new whey forward? *Endocrinology* **147**, 3171–3172.
25. Gaudel C, Nongonierma AB, Maher S, *et al.* (2013) A whey protein hydrolysate promotes insulinotropic activity in a clonal pancreatic β -cell line and enhances glycemic function in ob/ob mice. *J Nutr* **143**, 1109–1114.
26. Sakamoto E, Seino Y, Fukami A, *et al.* (2012) Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion. *J Diabetes Investig* **3**, 432–440.
27. Ben Lulu S, Coran AG, Mogilner JG, *et al.* (2010) Oral insulin stimulates intestinal epithelial cell turnover in correlation with insulin-receptor expression along the villus-crypt axis in a rat model of short bowel syndrome. *Pediatr Surg Int* **26**, 37–44.
28. Large V, Peroni O, Letexier D, *et al.* (2004) Metabolism of lipids in human white adipocyte. *Diabetes Metab* **30**, 294–309.